Organoids Inform an Aggressive Approach to Pancreatic Cancer
Medical oncologists, hematologists, gastroenterologists, pulmonologists, internists, surgeons, geneticists, palliative care specialists, basic and translational research scientists, residents, fellows, and medical students need to receive regular updates on advances in the diagnosis and management of hematologic disorders and malignancies. The series aims to expand the knowledge base of learners in these topic areas, improve their clinical competencies and research skills, enhance patient care, and improve outcomes.
Physicians, medical students, fellows, residents, and other health professionals.
At the conclusion of the session, the participants should be able to:
Describe standard of care treatments for sequencing and treatment options for patients with pancreatic cancer.
Discuss the emerging options for predictive biomarkers of therapeutic response in pancreatic cancer.
Identify patients eligible for multi-modal therapies, including radiotherapeutic and surgical approaches, in pancreatic cancer.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation